PPT-Rivaroxaban compared with enoxaparin for the prevention of

Alexander T Cohen On behalf of the MAGELLAN Steering Committee and Investigators Potential conflicts Dr AT Cohen is a medical consultant for and has received honoraria consultancy and clinical trial funding from many pharmaceutical companies including . Allyson Sarigianis, Pharm.D.. October 19, 2013. Objectives. Review current practice recommendations for prevention of stroke/systemic embolism in atrial fibrillation. Compare and contrast pharmacology between warfarin and target specific oral anticoagulants (TSOACs). (. N. OAC). Dan . Moellentin. , . PharmD. , BCPS, Associate Professor . Husson. University. Strokes in Atrial Fibrillation. 1/5 of strokes are caused by a. fib. 1/3 cardiac arrhythmias hospitalizations . EVI. dence. on . S. troke prevention . I. n patients with . a. T. rial. Fibrillation in the . U. nited . S. tates . Craig I. . Coleman. , . Matthias . Antz. , . Edgar . Simard, . Thomas . Evers, . Kevin . Effective PE Treatment Matters. PE is a potentially fatal consequence of DVT. PE is frequently . asymptomatic, and along with DVT, is associated with delayed diagnosis, making prompt treatment difficult. Sponsored by Bristol-Myers Squibb and Pfizer. Samuel Z. Goldhaber, MD. Brigham and Women’s Hospital. Harvard Medical School. On behalf of the ADOPT Executive Committee. November 13, 2011. Disclosures. Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators. Committees and . D. isclosures. Academic Executive Committee. E. Magnus Ohman, MB - Co-chair. C. Michael Gibson, MS, MD - Co-chair. Matthew T. Roe, MD, MHS. Stratified by Baseline CV Risk Category. Aspirin for Secondary Prevention of CV Disease. Anticoagulant Therapy in CAD. Warfarin -- WARIS-2. ATLAS ACS 2 -- TIMI 51. Rivaroxaban vs Placebo After ACS. COMPASS. Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial Kelley Branch, MD, MSc, on behalf of the COMPASS Steering Committee and Investigators Dr. Phil Wells on behalf of the EINSTEIN CHOICE Steering Committee and Investigators Weitz JI et al. N Engl J Med 2017 ( In Press) Rivaroxaban or Aspirin for Extended Treatment of Venous  Thromboembolism Dr NA Smith - Haematology Dept. Heart of England NHS Foundation Trust. Venous . thromboembolism. (VTE). Venous Ulcers. . PE . DVT . Post-thrombotic. syndrome. Death. . Deep vein . insufficiency. & safe anticoagulant prescribing. July 2020. Dr Clare Brown . Slides by Dr . Julia . Anderson. Department of Haematology. Royal Infirmary of Edinburgh. Plan for today. Where to locate the antithrombotic guidelines and protocols. Katie M. Groom, MBBS, PhD, FRANZCOG, CMFM; Lesley M. . McCowan. , MB ChB, MD, FRANZCOG, CMFM; Laura K. Mackay, BSc; . Arier. C. Lee, PhD; Joanne M. Said, MBBS, PhD. ,; . Stefan C. Kane, MBBS, FRANZCOG; Susan P. Walker, MBBS, MD, FRANZCOG, CMFM; . VTE death. ) for . rivaroxaban. vs. . enoxaparin. : 2.7% vs. 2.7%, p for . noninferiority. = 0.0025; at 35 days: 4.4% vs. 5.7%, p = 0.02. Clinically relevant bleeding at 10 days: . 2.8. % vs. 1.2%; at . Thromboembolism. Jatheesh mohan. BACKGROUND. Factor . XIa. inhibitors for the prevention and treatment of venous and arterial thromboembolism may be more effective and result in less bleeding than conventional anticoagulants..